Sitryx

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

R&D

Immunometabolism: Providing a new era of targeted medicine

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Neil Weir, CEO of Sitryx Therapeutics, a smaller biotech that specialises in immunometabolism – a rapidly

News

BridgeBio’s $250m raise heads latest biotech financings

BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido

Boehringer bets up to $500m on Sitryx immunology programme

Immunometabolism: Providing a new era of targeted medicine

BridgeBio’s $250m raise heads latest biotech financings

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks